Matisse Capital

Position in SPRY — ARS Pharmaceuticals, Inc.

CIK 1668256 PORTLAND, OR

Position in SPRY

as of Mar 31, 2026 · filed May 8, 2026 Compact

Position Value

$539,848

-$107,437 QoQ

Shares Held

67,229

+21.0% QoQ

Ownership

0.068%

of shares outstanding

% of Portfolio

0.28%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2025

5 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

Matisse Capital holds $7,147,288 across 4 Biotechnology names. SPRY ranks #2 (7.6% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	26,077	$5,964,592
2	SPRY	ARS Pharmaceuticals, Inc. This page	67,229	$539,848
3	WVE	Wave Life Sciences Ltd.	46,723	$338,741
4	FULC	Fulcrum Therapeutics, Inc.	39,649	$304,107

5 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$539,848	67,229	+21.0%	Shares	Sole	2026-05-08
2025-12-31	$647,285	55,561	-3.9%	Shares	Sole	2026-01-29
2025-09-30	$580,799	57,791	+1.9%	Shares	Sole	2025-10-29
2025-06-30	$989,659	56,714	+1.8%	Shares	Sole	2025-07-23
2025-03-31	$700,882	55,714	—	Shares	Sole	2025-04-24
No filing history on record for this holder in this stock.